Journal article
Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies
D Rosillon, L Baril, MR Del Rosario-Raymundo, CM Wheeler, SR Skinner, SM Garland, J Salmeron, E Lazcano-Ponce, CS Vallejos, T Stoney, B ter Harmsel, TYK Lim, SC Quek, G Minkina, SA McNeil, C Bouchard, KL Fong, D Money, A Ilancheran, A Savicheva Show all
Cancer Medicine | WILEY | Published : 2019
DOI: 10.1002/cam4.1879
Abstract
Background: Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti-HPV antibodies is uncertain. We examined the risk of HPV infections as defined by HPV DNA detection and cervical abnormalities among women >25 years in the Human Papilloma VIrus Vaccine Immunogenicity ANd Efficacy trial's (VIVIANE, NCT00294047) control arm. Methods: Serum anti-HPV-16/18 antibodies were determined at baseline and every 12 months in baseline DNA-negative women (N = 2687 for HPV-16 and 2705 for HPV-18) by enzyme-linked immunosorbent assay (ELISA) from blood samples. HPV infections were identified by polyme..
View full abstract